An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Key facts
- Who runs it
- AbbVie
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 10 Nov 2022
- Ended
- 8 Sept 2024
- Type of study
- Observational
- Record updated
- 24 March 2025
Who can take part
- Age
- 2 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Male or female participants aged 2-17 years old with body weight ≥ 10kg
- Diagnosis of polyarticular pJIA by treating physician
- Adalimumab (Humira®) treatment is indicated as per Chinese label and according to judgement of the physician to Chinese clinical practice guidelines for the diagnosis and treatment of juvenile idiopathic arthritis
- Participants or their parents/legal guardians are able and willing to give assent as well as informed consent approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) if applicable according to local law, and to comply with the requirements of this study protocol and Adalimumab (Humira ®) label
Who cannot take part
- Participants who cannot be treated with adalimumab according to Chinese Humira® label and by judgement of treating physician
- Participants who receive any biological disease-modifying anti-rheumatic drugs (bDMARDs) within 6 months prior to the screening visit or who are on concomitant use of any bDMARD
- Post menarche adolescent female subjects who are pregnant or breastfeeding or considering becoming pregnant during the study
- Participant is considered by the investigator or sub-investigator, for any reason, to be an unsuitable candidate for the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease affecting children, characterized by chronic synovitis with systemic multi-organ damage. Polyarticular juvenile idiopathic arthritis (pJIA) is a subtype of JIA defined as disease involving more than five joints in the first 6 months of disease. This study will assess how safe and effective adalimumab (Humira®) is in treating pediatric participants with pJIA in China real-world setting.
Read full original descriptionShow less
Adalimumab is an approved drug for the treatment of pJIA. Approximately 50 participants age 2 to 17 who are prescribed adalimumab for the treatment of pJIA in routine clinical practice will be enrolled at multiple sites in China.
Participants will receive adalimumab per their physician's usual prescription. Individual data will be collected for 52 weeks.
No additional study-related tests will be conducted during the routine physician visits. Only data which are routinely collected during a regular visit will be utilized for this study.
The group in the trial
- Pediatric Participants receiving adalimumab
Pediatric Participants receiving adalimumab for polyarticular juvenile idiopathic arthritis (pJIA)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-label, Multi-center, Post-marketing, Observational Study to Assess the Effectiveness and Safety of Adalimumab (Humira®) in Pediatric Patients With Polyarticular Juvenile Idiopathic Arthritis (pJIA) in China
- Record updated
- 24 March 2025